Blueprint Medicines Corp

Blueprint Medicines — Investor Presentation (January 2021)

29 slides from Blueprint Medicines's investor presentation, Jan 11, 2021

  1. Slide 1: Precision That Moves: Company Overview, January 2021

    Slide 1: Precision That Moves: Company Overview, January 2021

    © 2021 Blueprint Medicines Corporation R.S., living with systemic mastocytosis PRECISION THAT MOVES™ Staying one step ahead of disease JANUARY 2021 COMPANY OVERVIEW

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "

  3. Slide 3: Hopeful foundation, a new precision therapy platform

    Slide 3: Hopeful foundation, a new precision therapy platform

    Hopeful foundation A new precision therapy platform 2010 Hopeful reality ~2,600 patients treated with an approved or investigational Blueprint Medicines therapy 2021 Rob T. Living with GIST

  4. Slide 4: 2020: a transformational year for Blueprint Medicines

    Slide 4: 2020: a transformational year for Blueprint Medicines

    2020: a transformational year for Blueprint Medicines 4 Build commercial momentum Advance registration program for SM Strengthen pipeline with new programs ✓ AYAVKIT™ / AYVAKYT® (avapritinib) approved for PDGFRA-driven GIST in the U.S. and Europe1 ✓ GAVRETO™ (pralsetinib) approved for RET-altered NS

  5. Slide 5: Core mission and foundational principles

    Slide 5: Core mission and foundational principles

    Blueprint Medicines’ core mission and foundational principles 5 We aim to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible TRANSFORMATIVE BENEFIT PRECISION ADAPTIVE ABILITY RELENTLESS DRIVE FOCUS ON URGENT PATI

  6. Slide 6: A leader in precision oncology and hematology

    Slide 6: A leader in precision oncology and hematology

    A leader in precision oncology and hematology 6 ONCOLOGY HEMATOLOGY RARE DISEASES PRIMARY FOCUS OPPORTUNISTIC PORTFOLIO AREAS OF FOCUS SYSTEMIC MASTOCYTOSIS LUNG CANCER THERAPEUTIC AREA LEADERSHIP Not for promotional use.

  7. Slide 7: Pipeline and partnership footnotes

    Slide 7: Pipeline and partnership footnotes

    1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, pralsetinib and fisogatinib in Mainland China, Hong Kong, Macau and Taiwan. 3. Approved in the U.S. for the treatment of adults with unresectable or metastatic GIST harbori

  8. Slide 8: 2021 roadmap for precision medicine leadership

    Slide 8: 2021 roadmap for precision medicine leadership

    2021 roadmap for precision medicine leadership 8 Accelerate global adoption of AYVAKIT and GAVRETO Advance a new wave of therapeutic candidates toward clinical proof-of-concept Further expand the company’s precision therapy pipeline Not for promotional use.

  9. Slide 9: 2021 roadmap for precision medicine leadership

    Slide 9: 2021 roadmap for precision medicine leadership

    2021 roadmap for precision medicine leadership 9 Accelerate global adoption of AYVAKIT and GAVRETO Advance a new wave of therapeutic candidates toward clinical proof-of-concept Further expand the company’s precision therapy pipeline Not for promotional use.

  10. Slide 10: Two precision therapies first approved in 2020 with clear pathways for growth

    Slide 10: Two precision therapies first approved in 2020 with clear pathways for growth

    Two precision therapies first approved in 2020 with clear pathways for growth 10 • Approved for unresectable or metastatic PDGFRA exon 18 mutant GIST • Approved for advanced or metastatic RET-altered NSCLC, MTC and other thyroid cancers CORE VALUE OPPORTUNITY • sNDA submitted to FDA for advanced SM

  11. Slide 11: Systemic mastocytosis is driven by KIT D816V

    Slide 11: Systemic mastocytosis is driven by KIT D816V

    Systemic mastocytosis is driven by KIT D816V Mild symptoms Non-Advanced SM Severe symptoms Indolent SM (ISM) • Some progression to advanced disease (4%)2 • Long-term morbidity, including life- threatening anaphylaxis, frequent GI upset, and debilitating fatigue3 Smoldering SM (SSM) • Increased organ

  12. Slide 12: Significant initial target patient population with additional growth potential

    Slide 12: Significant initial target patient population with additional growth potential

    Significant initial target patient population with additional growth potential Major markets include U.S., France, Germany, Italy, Spain, the United Kingdom and Japan. 1. Cohen S et al Br J Haematol (2014) 166(4):521-8 and World Bank Population estimates. 12 ~75,000 PATIENTS IN MAJOR MARKETS ~1/3 DI

  13. Slide 13: Testing initiatives to facilitate SM patient identification

    Slide 13: Testing initiatives to facilitate SM patient identification

    Pursuing a range of testing initiatives to facilitate SM patient identification 13 ENHANCE TESTING INFRASTRUCTURE CHANGE TESTING BEHAVIOR DATA AGREEMENTS SUPPORT TO STAND UP TESTING SPONSORED TESTING INITIATIVES AWARENESS & EDUCATION Expand testing footprint Optimize testing protocols Support access

  14. Slide 14: AYVAKIT registration program in advanced systemic mastocytosis

    Slide 14: AYVAKIT registration program in advanced systemic mastocytosis

    AVYAKIT registration program in advanced systemic mastocytosis 14 mIWG, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) response criteria. AdvSM, advanced systemic mastocytosis; QD, once daily. Ad

  15. Slide 15: Consistently high ORRs and prolonged duration of response across trials

    Slide 15: Consistently high ORRs and prolonged duration of response across trials

    Consistently high ORRs and prolonged duration of response across trials Top-line EXPLORER and PATHFINDER data presented in September 2020. Data cutoff: May 27, 2020 for EXPLORER and June 23, 2020 for PATHFINDER, with response assessments per central review completed in September 2020. CR, complete r

  16. Slide 16: Deep reductions in mast cell burden and resolution of organ damage

    Slide 16: Deep reductions in mast cell burden and resolution of organ damage

    Deep reductions in mast cell burden and resolution of organ damage 16 -100 -80 -60 -40 -20 0 20 M a x i m u m P e r c e n t C h a n g e f r o m B a s e l i n e BLU-285-2202 BLU-285-2101 Study SERUM TRYPTASE1 -100 -80 -60 -40 -20 0 20 40 60 M a x i m u m P e r c e n t C h a n g e f r o m B a s e l i

  17. Slide 17: AYVAKIT demonstrated improved tolerability at 200 mg QD

    Slide 17: AYVAKIT demonstrated improved tolerability at 200 mg QD

    AYVAKIT demonstrated improved tolerability at 200 mg QD 17 Treatment Emergent AEs ≥ 20%, All Grades* 200 mg n=81 (%) All doses N=148 (%) Peripheral Edema 39 ( 48.1) 65 ( 43.9) Periorbital Edema 32 ( 39.5) 81 ( 54.7) Thrombocytopenia 28 ( 34.6) 55 ( 37.2) Anemia 26 ( 32.1) 65 ( 43.9) Diarrhea 23 ( 28

  18. Slide 18: Plan to complete enrollment of PIONEER registrational Part 2 in mid-2021

    Slide 18: Plan to complete enrollment of PIONEER registrational Part 2 in mid-2021

    Plan to complete enrollment of registrational Part 2 of PIONEER trial of AYVAKIT in non-advanced SM in mid-2021 18 ISM, indolent system mastocytosis; ISM-SAF, indolent systemic mastocytosis – symptom assessment form; RP2D, recommended phase 2 dose. Non-advanced SM RP2D 25 mg QD PART 1 DOSE ESCALATIO

  19. Slide 19: PIONEER Part 1 data in non-advanced SM

    Slide 19: PIONEER Part 1 data in non-advanced SM

    PIONEER Part 1 data showed AYVAKIT 25 mg QD reduces symptoms and mast cell burden in non-advanced SM Presented at EAACI Virtual 2020 Congress in June 2020. Data cutoff: March 31, 2020. *24 weeks or last assessment before, if 24 weeks not available. EAACI, European Academy of Allergy and Clinical Imm

  20. Slide 20: Safety results for AYVAKIT 25mg QD similar to placebo at 16 weeks

    Slide 20: Safety results for AYVAKIT 25mg QD similar to placebo at 16 weeks

    Safety results for AYVAKIT 25mg QD are similar to placebo at 16 weeks1 1. Data presented in March 2020 at AAAAI annual meeting. Data cutoff: December 27, 2019. 2. Data cutoff: March 31, 2020. 20 AE in >15% of placebo or avapritinib arms avapritinib Preferred term Placebo n=9 25 mg n=10 % of subjects

  21. Slide 21: AYVAKIT is the only clinically validated, highly potent KIT D816V inhibitor

    Slide 21: AYVAKIT is the only clinically validated, highly potent KIT D816V inhibitor

    AYVAKIT is the only clinically validated, highly potent inhibitor of KIT D816V, the genetic driver of SM 1. Top-line EXPLORER and PATHFINDER data presented in September 2020. Data cutoff: May 27, 2020 for EXPLORER and June 23, 2020 for PATHFINDER, with response assessments per central review complet

  22. Slide 22: 2021 roadmap for precision medicine leadership

    Slide 22: 2021 roadmap for precision medicine leadership

    2021 roadmap for precision medicine leadership 22 Accelerate global adoption of AYVAKIT and GAVRETO Advance a new wave of therapeutic candidates toward clinical proof-of-concept Further expand the company’s precision therapy pipeline Not for promotional use.

  23. Slide 23: Multiple additional opportunities for transformative medicines

    Slide 23: Multiple additional opportunities for transformative medicines

    Multiple additional opportunities for transformative medicines 23 PROGRAM (TARGET) DESCRIPTION / STATUS BLU-263 (KIT D816V) Non-advanced SM and other mast cell disorders • Well-tolerated in Phase 1 healthy volunteer trial • Plan to initiate Phase 2 trial in non-advanced SM in mid-2021 BLU-945 (tripl

  24. Slide 24: Our vision for transforming treatment of EGFR+ NSCLC

    Slide 24: Our vision for transforming treatment of EGFR+ NSCLC

    Our vision for transforming treatment of EGFR+ NSCLC 1. Girard N. Future Oncol. 2018;14(11):1117–1132. 2. Leonetti, A et al. British Journal of Cancer. 2019;121:725–737. 1L, first-line treatment; 2L, second-line treatment; 3L, third-line treatment. 24 1ST GEN EGFR TKI OSIMERTINIB TRIPLE MUTANT INHIB

  25. Slide 25: Foundational BLU-945 preclinical data presented at ESMO 2020

    Slide 25: Foundational BLU-945 preclinical data presented at ESMO 2020

    Foundational BLU-945 preclinical data presented at ESMO 2020 support initiation of clinical development in 1H 2021 Data presented at ESMO 2020 virtual conference in September 2020. 25 SUBNANOMOLAR POTENCY EXCELLENT SELECTIVITY ROBUST SINGLE AGENT ACTIVITY COMBINATION POTENTIAL PRECLINICAL CNS ACTIVI

  26. Slide 26: 2021 roadmap for precision medicine leadership

    Slide 26: 2021 roadmap for precision medicine leadership

    2021 roadmap for precision medicine leadership 26 Accelerate global adoption of AYVAKIT and GAVRETO Advance a new wave of therapeutic candidates toward clinical proof-of-concept Further expand the company’s precision therapy pipeline Not for promotional use.

  27. Slide 27: Constant expansion of highly productive research platform

    Slide 27: Constant expansion of highly productive research platform

    Constant expansion of highly productive research platform 27 PLAN TO EXPAND PIPELINE WITH ONE OR MORE DEVELOPMENT CANDIDATES WORLD-CLASS EXPERTISE IN CATALYTIC KINASE INHIBITION MOLECULAR TARGETING THERAPEUTIC DESIGN Deep biological insights across core areas of focus Vast genomic datasets and compu

  28. Slide 28: 2021 roadmap: strategies and key goals

    Slide 28: 2021 roadmap: strategies and key goals

    2021 roadmap for precision medicine leadership: strategies and key goals 28 Accelerate global adoption of AYVAKIT and GAVRETO Advance a new wave of therapeutic candidates toward clinical proof-of-concept Further expand the company’s precision therapy pipeline • Obtain FDA approval and launch AYVAKIT

  29. Slide 29: Strongest financial position in our history

    Slide 29: Strongest financial position in our history

    Blueprint Medicines is in the strongest financial position in our history 1. Includes stock-based compensation expense of $8.6M in 2020 and $7.7M in 2019. 2. Includes stock-based compensation expense of $11.0M in 2020 and $7.3M in 2019. 29 Statement of Operations (unaudited) Three Months Ended 9/30/

Source: SEC EDGAR · 8-K filed Jan 11, 2021

More decks from Blueprint Medicines Corp